<DOC>
	<DOCNO>NCT02782481</DOCNO>
	<brief_summary>This multicenter , randomize , double blind , placebo control parallel group clinical study . Following screening period 28 day , eligible subject randomize receive adjunct treatment oral LD/DDI ( Dopa Decarboxylase Inhibitor ) continuous subcutaneous infusion ND0612 match placebo 16 week .</brief_summary>
	<brief_title>A Clinical Study Investigating Efficacy , Tolerability , Safety Continuous Subcutaneous ND0612 Infusion Given Adjunct Treatment Oral Levodopa Patients With Parkinson 's Disease With Motor Fluctuations</brief_title>
	<detailed_description>This phase III randomize , double-blind , placebo control , parallel group clinical study conduct 150 subject idiopathic PD experience motor complication despite optimized anti-PD therapy . The study investigate efficacy , safety tolerability continuous SC infusion ( 16 week ) ND0612 compare placebo infusion . The treatment period comprise 4-week adjustment period time ND0612 infusion dose remain constant oral LD/DDI dose decrease increase back Baseline level . All anti-PD treatment must remain constant . During maintenance period ( Weeks 5 16 ) anti-PD medication include ND0612/placebo remain constant .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Key 1 . Male female PD subject race age 3080 year 2 . PD diagnosis consistent UK Brain Bank Criteria . 3 . Modified Hoehn &amp; Yahr scale `` ON '' state â‰¤3 4 . Subjects must experience motor fluctuation experience average least 2 hour daily `` OFF '' state 5 . Taking least 4 doses/day IR LD/DDI ( least 3 doses/day Rytary ) taking , take therapeutic dos least 2 class antiPD medication . 6 . Subjects must stable dos antiPD medication least 28 day Baseline ( Day 1 ) . 7 . Subject and/or study partner must demonstrate ability keep accurate diary entry PD symptom ( `` ONOFF '' diary ) least 75 % concordance study rater end diary training session end screening period . 8 . Mini Mental State Examination ( MMSE ) score &gt; 26 . 9 . Female subject must surgically sterile ( hysterectomy , bilateral oophorectomy , tubal ligation ) , postmenopausal ( defined cessation menses least 1 year ) , willing practice highly effective method contraception . Key 1 . Atypical secondary parkinsonism . 2 . Psychosis hallucination past 6 month . 3 . Subjects clinically significant unstable medical , surgical , psychiatric condition laboratory abnormality , opinion Investigator EAC , represent safety risk , make subject unsuitable study entry potentially unable complete aspect study . 4 . Clinically significant ECG abnormality . 5 . Renal liver dysfunction may alter drug metabolism include Screening visit serum level creatinine &gt; 1.3 mg/dL , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2x upper limit normal ( ULN ) , total bilirubin &gt; 2.5 mg/dL . 6 . Positive serum serology Hepatitits B Virus ( HBV ) , Hepatitits C Virus ( HCV ) Human Immunodeficiency Virus ( HIV ) Screening visit 7 . Any malignancy 5 year prior randomization exclude basal cell carcinoma skin cervical carcinoma situ successfully treat 8 . Use prohibit medication per protocol 9 . Subjects previously undergone treatment PD neurosurgical intervention ( e.g. , pallidotomy , thalamotomy , transplantation , deep brain stimulation procedure ) , Duodopa/Duopa , continuous dopaminergic apomorphine infusion .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>